Look behind the lecture: the importance of patient engagement across the healthcare continuum
FDA joins multi-stakeholder effort to leverage real-world data in COVID-19 diagnostic testing space
[UPDATE] FDA allows expanded use of certain health monitoring devices, to limit in-person patient–provider contact during the COVID-19 outbreak
COVID-19: side effects of healthcare’s digitalization in England – harnessing the positives and mitigating the negatives
Look behind the lecture: the relevance of registry and real-world data throughout a product’s lifecycle
ISPOR 2020 – inside the second plenary: moving from population health to 'precision population health'
ISPOR 2020: do managed entry agreements for ATMPs exist in Germany? Curative and genetic therapies abstract highlights
ISPOR 2020 – inside the first plenary: both necessity and science give rise to invention
ISPOR 2020: how may we enable faster access to multi-indication orphan products? Rare disease and orphan drug abstract highlights
Events, ISPOR, Health technology assessment, Medical devices, pharmaceuticals and vaccines, Methodology, Real-world evidence, Stakeholder engagement
[ON DEMAND] Improving efficiency in health technology assessment with advanced software: a panel discussion
Estimating the opportunity–cost-based cost–effectiveness threshold: a peek behind the podcast
[UPDATE] Could a mobile app for contact tracing help in the fight against COVID-19?
Patient-reported outcomes in health technology assessment: an interview with Olivier Chassany